论文部分内容阅读
目的对比不应用糖皮质激素与应用不同糖皮质激素方案治疗自身免疫性甲状腺疾病(AITD)的安全性、有效性,总结用药经验。方法262例AITD患者,按入院顺序分为A组(87例)、B组(87例)、C组(88例)。A组给予常规对抗治疗、对症治疗,B组口服糖皮质激素治疗,C组静脉应用糖皮质激素治疗。对比三组患者的治疗效果。结果治疗后,三组生存质量测定量表(WHOQOL-100)评分均高于治疗前,B、C组高于A组,差异均具有统计学意义(P<0.05);B、C组控制率、控制率+显效率高于A组,无效率低于A组,差异均具有统计学意义(P<0.05);A组不良反应发生率为0,B组为4.60%,C组为6.82%;B、C组均高于A组,差异均具有统计学意义(P<0.05)。结论糖皮质激素用于AITD的治疗可增进疗效,减轻症状,提高患者生存质量,口服与静脉用药疗效无显著差异,但静脉用药可能增加不良反应发生风险。
Objective To compare the safety and efficacy of glucocorticoid and different glucocorticoid regimens in the treatment of autoimmune thyroid disease (AITD). Methods A total of 262 AITD patients were divided into group A (87 cases), group B (87 cases) and group C (88 cases) according to the order of admission. A group given conventional antagonistic treatment, symptomatic treatment, B group oral glucocorticoid treatment, C group intravenous glucocorticoid treatment. Comparison of the treatment effect of three groups of patients. Results After treatment, the WHOQOL-100 scores were higher than those before treatment, while those in groups B and C were higher than those in group A (P <0.05). The rates of control in groups B and C (P <0.05). The incidence of adverse reactions in group A was 0%, in group B was 4.60%, in group C was 6.82% ; Group B and C were higher than Group A, the differences were statistically significant (P <0.05). Conclusion Glucocorticoids used in AITD treatment can improve the curative effect, relieve the symptoms and improve the quality of life of patients. There is no significant difference between oral and intravenous drugs, but intravenous drug may increase the risk of adverse reactions.